Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
← catalyst calendarNCT07549698 · readout ≤ 2,691 d
Sponsored by CRISPR Therapeutics AG (industry) · CRSP — their whole pipeline →.
Phase
Phase 1/2
Status
Recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
60estimated
Sites
10
Countries
Germany, Spain, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | Jun 2026 | estimated | When the study began enrolling |
| Primary completion | Dec 2033 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Dec 2033 | estimated | The whole study's end, after follow-up |
| First posted | 2026-04-24 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Warm Autoimmune Hemolytic Anemia (WAIHA)
- ITP - Immune Thrombocytopenia
- Warm Autoimmune Hemolytic Anemia
- Immune Thrombocytopenic Purpura
Intervention
- Biological: CTX112 — also filed as Zugocabtagene geleucel, zugo-cel
Primary outcome
what the primary-completion date above is the date OFTo evaluate the safety of CTX112 in adult participants with refractory hematologic autoimmune diseases, including ITP or wAIHA.
measured From CTX112 infusion up to 28 days post infusion.
Permalink · CRSP's whole pipeline · Catalyst calendar · Every registered study · What changed